Literature DB >> 189604

Herpes zoster and impaired cell-associated immunity to the varicella-zoster virus in patients with Hodgkin's disease.

J C Ruckdeschel, S C Schimpff, A C Smyth, M R Mardiney.   

Abstract

Thirty-two patients with Hodgkin's disease and 12 normal donors were studied for their in vitro lymphocyte responsiveness to a membrane-associated varicella-zoster (VZ) antigen. When compared to the normal donors, patients with Hodgkin's disease in whom radiotherapy was recently completed and those with active, recurrent disease had markedly impaired cell-associated immunity to VZ antigen. In addition, there was a suggestion that patients in long-term remission who had received primary combined modality therapy (radiotherapy plus chemotherapy) had an impaired response when compared to normal persons or to patients who had received single modality therapy. Newly diagnosed, untreated patients with Hodgkin's disease did not differ significantly from normal persons as a group but two of six were unresponsive to the VZ antigen whereas all normal subjects were responsive. Most patients in remission for at least one year following therapy had normal in vitro responsiveness. In two patients herpes zoster developed after the demonstration of absent in vitro lymphocyte reactivity to the VZ antigen.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 189604     DOI: 10.1016/0002-9343(77)90352-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  11 in total

1.  Cellular and humoral immune responses to varicella-zoster virus in immunocompromised patients during and after varicella-zoster infections.

Authors:  A A Gershon; S P Steinberg
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

2.  Cell-mediated immunity to varicella-zoster virus measured by virus inactivation: mechanism and blocking of the reaction by specific antibody.

Authors:  A A Gershon; S P Steinberg
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

3.  Amikacin pharmacokinetics during continuous ambulatory peritoneal dialysis.

Authors:  B D Smeltzer; M S Schwartzman; J S Bertino
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

4.  Antibody-dependent cell-mediated cytotoxicity to Varicella zoster.

Authors:  J Babbage; A Sigfusson; R L Souhami
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

5.  Specific in vitro antibody response to varicella zoster.

Authors:  R L Souhami; J Babbage; R E Callard
Journal:  Clin Exp Immunol       Date:  1981-10       Impact factor: 4.330

6.  Defective in vitro antibody production to Varicella zoster and other virus antigens in patients with Hodgkin's disease.

Authors:  R L Souhami; J Babbage; A Sigfusson
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

7.  Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma.

Authors:  A M Arvin; R B Pollard; L E Rasmussen; T C Merigan
Journal:  J Clin Invest       Date:  1980-04       Impact factor: 14.808

8.  Medical staff conference: Hodgkin disease.

Authors: 
Journal:  West J Med       Date:  1977-12

9.  Varicella-zoster virus as a live vector for the expression of foreign genes.

Authors:  R S Lowe; P M Keller; B J Keech; A J Davison; Y Whang; A J Morgan; E Kieff; R W Ellis
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

10.  Aminoglycoside dosing in renal transplant patients. Comparison of nomogram and individualized pharmacokinetic methods in patients with shifting renal function.

Authors:  R W Tofte; D M Canafax; R L Simmons; P K Peterson
Journal:  Ann Surg       Date:  1982-03       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.